14
Views
2
CrossRef citations to date
0
Altmetric
Editorial

Publishing the results of the estrogen-only arm of WHI

Pages 117-119 | Published online: 03 Jul 2009

References

  • Writing Group for the Women's Health Initia-tive Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal wo-men: principal results from the Women's Health Initiative randomized controlled trial. J Am Med Assoc 2002;288:321–33
  • Shapiro S. Risks of estrogen plus progestin therapy: a sensitivity analysis of findings in the Women's Health Initiative randomized con-trolled trial. Climacteric 2003;6:302–10
  • Ettinger B, Grady D, Tosteson ANA, Pressman A, Macer JL. Effects of Women's Health Initiative on women's decision to discontinue postmenopausal hormone therapy. Obstet Gy-necol 2003;102:1225–32
  • MacLennan AH, Taylor AW, Wilson DH. Hormone therapy use after the Women's Health Initiative. Climacteric 2004;7:138–42
  • Paine JP, Stocks NP, Ramsay EN, Ryan P, MacLennan AH. Use and perception of hormone therapy following media reports of the Women's Health Initiative: survey of Australian WISDOM participants. Climacteric 2004;7:143–52
  • Yates J, Barrett-Connor E, Barlas S, Chen Y, Miller PD, Sins ES. Rapid loss of hip fracture protection after estrogen cessation: evidence from the National Osteoporosis Risk Assess-ment. Obstet Gynecol 2004;103:440–6
  • Creasman WT, Hoel DH, DiSara PJ. WHI: now that the dust has settled. Am J Obstet Gynecol 2003;189:621–6
  • Sturdee D, MacLennan AH. Should epidemiol-ogy, the media and quangos determine clinical practice? Climacteric 2004;7:1–2
  • Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;362:419–27
  • Vickers M, Meade T, Darbyshire J. WISDOM: history and early demise — was it inevitable? Climacteric 2002;5:317–25
  • Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestogen and the risk of coronary heart disease. N Engl J Med 2003;349:532–4
  • Thomas T, Rhodin J, Clark L, Garces A. Progestins initiate adverse events of menopausal estrogen therapy. Climacteric 2003;6:293–301
  • MacLennan AH, MacLennan A, Wilson D. The prevalence of oestrogen replacement therapy in South Australia. Maturitas 1993;16:175–83

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.